EGFR and non-small cell lung carcinoma: Moreover, with regard to the treatment of surgically treated NSCLC patients with postoperative disease progression, a Japanese research team conducted a study using the same patient group setting as ours and reported a significantly longer post-recurrence survival of 49 months for EGFR-mutated patients receiving EGFR-TKIs than the 12 months for patients who did not, showing that EGFR-TKIs also contribute to better post-recurrence outcomes [19].